早期症候性アルツハイマー病の米国参加者を対象とした、ドナネマブ (LY3002813) と通常のケアと通常のケアのみの実際の比較研究
米国の早期症候性アルツハイマー病患者におけるドナネマブと通常のケアと通常のケアのみの長期にわたる実世界の比較有効性 (TRAILBLAZER-REAL US)
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- 電話番号:1-317-615-4559
- メール:clinical_inquiry_hub@lilly.com
研究場所
-
-
Alabama
-
Huntsville、Alabama、アメリカ、35805-4046
- 募集
- Rehabilitation & Neurological Services
-
主任研究者:
- Belinda Savage-Edwards
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population will consist of a donanemab plus usual care group and a usual care alone group. Participants will be enrolled 1:2 into donanemab plus usual care and usual care alone groups to allow enough participants in the usual care group to be matched with participants in the donanemab group to enable robust comparative effectiveness analyses.
説明
Inclusion Criteria:
Participants
- are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records [EHR] is required prior to screening)
- have a Telephone Interview for Cognitive Status (TICS) score of ≥21
- presence of amyloid beta (Aβ) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid [CSF]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)
- have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and
- have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.
Exclusion Criteria:
- have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)
- have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (>12 months) institutional-level care, serious psychiatric illness, etc.)
- are currently enrolled or intend to enroll in a clinical trial of another investigational product, and
- have contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Donanemab Group + Usual Care
Participants will receive open-label (unblinded) donanemab intravenously (IV) and Usual Care |
Administered IV
他の名前:
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
|
Usual Care Group
Participants will receive usual care. |
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS])
時間枠:Up to 5 Years
|
The DS is a caregiver-reported outcome assessing the need for daily in-home or institutional assistance by participants with AD. The DS is completed as a structured interview with a knowledgeable caregiver or study partner. The scale is composed of 13 items evaluating progressive needs for assistance. The total score ranges from 0 to 15, with higher scores indicating a greater degree of dependence on external support. |
Up to 5 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ベースラインで依存レベルが 3 未満の参加者のサブグループの独立性を失うまでの時間(DS から導出された依存レベル ≥3)
時間枠:最長5年
|
最長5年
|
|
|
DS 合計スコアのベースラインからの経時変化 (半年ごと)
時間枠:ベースライン、最長 5 年間
|
ベースライン、最長 5 年間
|
|
|
P-LSQ によって評価された在宅医療におけるベースラインからの時間の経過に伴う変化 (半年ごとに評価)
時間枠:ベースライン、最長 5 年間
|
ベースライン、最長 5 年間
|
|
|
P-LSQ によって評価された運転状態のベースラインからの時間の経過に伴う変化 (半年ごとに評価)
時間枠:ベースライン、最長 5 年間
|
ベースライン、最長 5 年間
|
|
|
Time to Institutionalization from Baseline for the Subgroup of Participants not Institutionalized at Baseline
時間枠:Up to 5 Years
|
Participants who endorse, "Assisted living facility" or "Skilled nursing facility, nursing home, hospice" as their primary residence on the participant lifestyle status Questionnaire (P-LSQ) will be considered institutionalized. |
Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Functional Assessment Questionnaire (FAQ) Total Score
時間枠:Baseline, Up to 5 Years
|
The FAQ is a brief, 10-item caregiver-reported outcome measure assessing performance on functional activities impacted early during AD. The maximum total score is 30, with higher scores indicating greater impairment. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Neuropsychiatric Inventory (NPI-Q) Total Severity Score
時間枠:Baseline, Up to 5 Years
|
The NPI-Q is a brief, caregiver-reported assessment of neuropsychiatric symptoms associated with dementia. The NPI-Q yields total scores for Severity and Distress, reflecting the sum of ratings across all domains, with higher scores indicating a greater degree of symptom severity and caregiver distress, respectively. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Zarit Burden Inventory-short version (ZBI-12) total score
時間枠:Baseline, Up to 5 Years
|
ZBI is a caregiver-reported instrument used widely to evaluate caregiver burden associated with AD and other diseases such as multiple sclerosis, congestive heart failure, and cancer. Items on the ZBI-12 assess caregiver stress, time available for self, and the impact of caring on the caregiver's social life. Responses are provided on a 5-point Likert scale (never=0, nearly always=4). The ZBI-12 total score has a range of 0 to 48, with higher scores indicating greater caregiver burden. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Living Situation as Assessed by the Participant Lifestyle Questionnaire (P-LSQ)
時間枠:Baseline, Up to 5 Years
|
The P-LSQ is a brief, sponsor-created questionnaire used to collect supplementary data regarding participants' living environment, home healthcare needs, and driving status that is not captured elsewhere. |
Baseline, Up to 5 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 18721
- I5T-MC-AACS (その他の識別子:Eli Lilly and Company)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共有時間枠
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。